The FDA Just Opened the Door to Prescribing Magic Mushrooms
The FDA held a landmark public hearing on psychedelic therapy access and safety, and it wasn't asking *if* these drugs should be approved. It was asking *how*. With Compass Pathways' psilocybin potentially months from a historic first approval, the real debate is just getting started.
A Four-Hour Meeting That Could Change Psychiatry Forever
On September 14, 2026, a room full of doctors, veterans, pharmacists, and therapists sat inside the FDA's White Oak Campus in Silver Spring, Maryland, and made their case for something that would have sounded absurd a decade ago: legal, prescription psychedelic therapy.
The FDA's public hearing on psychedelic access and safety ran from 12:30 p.m. to 4:30 p.m. ET, with both in-person and virtual testimony. It was part policy discussion, part emotional plea. And the timing wasn't accidental. The first-ever FDA approval of a psychedelic drug could be months away.
Compass Pathways, a UK-based biotech, is in a rolling review with the FDA for COMP360, a synthetic psilocybin designed to treat treatment-resistant depression (the kind that doesn't respond to conventional antidepressants). Final submission of its application is expected by the end of 2026. If approved, it would be the first classic psychedelic to earn an FDA stamp of approval, ever.
That's not a minor regulatory milestone. That's a tectonic shift.
Why the FDA Held This Hearing Now
Think of it like a town hall before a neighborhood rezoning vote. The FDA knows what's coming. It's preparing the framework for a world where psychedelics sit in pharmacy inventories, not just research labs.
The agency issued its first formal guidance for psychedelic clinical trials back in June 2023. In early 2024, it partnered with the Reagan-Udall Foundation for a public meeting on psychedelic study design. And in April 2026, it granted priority vouchers to three programs: Compass Pathways' psilocybin, Usona Institute's psilocybin, and Transcend Therapeutics' methylone.
All of that has been building toward this moment. The September hearing was the FDA essentially asking the public: How do we do this right?
The topics on the table were exactly what you'd expect at this stage: safety standards, patient access, provider training and credentialing, and data requirements. Not "should we approve psychedelics?" but "when we do, what guardrails do we need?"
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Ghost of MDMA's Rejection Still Haunts the Room
If you're wondering why the FDA is being so methodical, look at what happened with MDMA.
In June 2024, the FDA's advisory committee reviewed Lykos Therapeutics' MDMA-assisted therapy for PTSD and voted against approval. The committee flagged problems with functional unblinding (patients could easily tell whether they got the real drug or placebo, which muddied the results) and broader trial-design issues. Two months later, the FDA issued a complete response letter rejecting the application and requesting an additional Phase 3 study.
That rejection was a gut punch to the psychedelic therapy movement. It also served as a cautionary tale: enthusiasm alone won't get a drug approved. The science has to hold up under scrutiny, and the regulatory framework has to account for risks that are genuinely unusual.
Psychedelic therapy sessions can last six to twelve hours. The drugs affect perception, memory, and identity. Dr. Lida Fatemi, who testified at the September hearing, argued that this kind of care demands specific provider training because of how deeply it touches vulnerable parts of the mind.
"Approval Alone Is Not Access"
The hearing drew a wide range of voices. Speakers included Columbia University's Heidi Allen and representatives from the Psychedelic Medicine Association. Edward Jacobs of Johns Hopkins supported maintaining strong safeguards.
But a recurring theme kept surfacing, as captured in Reuters' coverage: a therapy is not meaningful if patients cannot access it. And access is about a lot more than an approval letter.
Consider the logistics. You need trained therapists who can supervise half-day sessions. You need certified treatment sites. You need insurance companies willing to reimburse for something that looks nothing like a 15-minute psychiatry appointment. Without those pieces, critics warned, psychedelic therapy becomes a concierge service for the wealthy.
The FDA appears to be taking this seriously. Its 2026 final guidance on psychedelic drug development explicitly tells drug sponsors to consider the potential need for a REMS (Risk Evaluation and Mitigation Strategy), which is basically a safety playbook that can include certified prescribers, specialized treatment sites, and patient monitoring requirements. That's a stronger stance than the 2023 draft guidance, which treated REMS as more of an edge case.
There's also the scheduling question. Classic psychedelics remain Schedule I under federal law, the same category as heroin. Even after FDA approval, the DEA would need to reschedule the approved formulation before doctors could prescribe it. Think of it as a two-key system: the FDA unlocks one door, and the DEA has to unlock the other.
The Market Is Already Pricing In a New Era
Investors aren't waiting for the approval to place their bets. The global psychedelic therapeutics market sits at roughly $2.9 billion in 2025, with projections putting it around $3.4 billion in 2026. By the early 2030s, analysts expect it to balloon into the $11 to $16 billion range.
Psilocybin is the molecule driving the most excitement. The company roster reads like a who's who of biotech ambition: Compass Pathways, MindMed, atai Life Sciences, Cybin, and even bigger players like Johnson & Johnson and Otsuka Pharmaceutical are in the mix.
For a drug class that was considered fringe science five years ago, that's a remarkable amount of corporate money on the table.
The Tightrope Walk Ahead
What makes this moment so fascinating is the tension at its core. Patient advocacy groups are pushing hard for broader access, harm-reduction infrastructure, and lived-experience inclusion in policy design. Organizations like PsyPAN argue that patients should help shape research and care from the ground up.
Meanwhile, the psychiatric establishment is urging caution. The American Psychiatric Association has said that FDA determination of safety and effectiveness must remain the foundation for clinical use, and it has cautioned against any use outside approved research settings until the evidence is stronger.
Both sides have a point. The patients who've exhausted every conventional option deserve a chance at something new. But the risks (mania, psychosis, prolonged dissociation, and the potential for boundary violations in therapy settings) are real and unusual. This isn't a pill you take at home. It's a supervised, hours-long experience that fundamentally alters consciousness.
The FDA's hearing was, in a sense, the agency acknowledging that it can't solve this alone. It needs input from doctors, patients, ethicists, and payers to build a system that works.
What Comes Next
Compass Pathways is expected to complete its NDA submission by Q4 2026. If the FDA follows its typical review timeline, a decision could come in 2027. That would make COMP360 the first classic psychedelic ever approved for medical use in the United States.
But approval is just the starting gun. The real race is building an ecosystem that can deliver these therapies safely, equitably, and at scale. If the FDA's September hearing proved anything, it's that everyone agrees on the destination. They're still arguing about the map.
Deals & M&A5 min read
Novo Nordisk Just Walked Away from a $285M Obesity Bet. Why?
Novo Nordisk just killed a $285 million partnership with Ascendis Pharma to develop a once-monthly GLP-1 obesity shot. In the middle of the biggest obesity drug race in history, why would you hand back that asset? The answer says a lot about where the market is heading.
